These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 31285291)

  • 21. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological treatments for severe asthma.
    Assaf SM; Hanania NA
    Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):379-386. PubMed ID: 31169594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug Development and Biologics in Asthma. A New Era.
    Doyle R
    Ann Am Thorac Soc; 2016 Mar; 13 Suppl 1():S83-4. PubMed ID: 27027958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs.
    Parulekar AD; Kao CC; Diamant Z; Hanania NA
    Curr Opin Pulm Med; 2018 Jan; 24(1):50-55. PubMed ID: 29036019
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benralizumab (Fasenra) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):33-35. PubMed ID: 29485975
    [No Abstract]   [Full Text] [Related]  

  • 27. Childhood asthma in the new omics era: challenges and perspectives.
    Golebski K; Kabesch M; Melén E; Potočnik U; van Drunen CM; Reinarts S; Maitland-van der Zee AH; Vijverberg SJH;
    Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):155-161. PubMed ID: 31985545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biologics for Asthma and Risk of Infection: Cause for Concern?
    Lopes JP; Desai M
    Immunol Allergy Clin North Am; 2019 Aug; 39(3):429-445. PubMed ID: 31284931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologics in severe asthma: the overlap endotype - opportunities and challenges.
    Bakakos A; Loukides S; Usmani OS; Bakakos P
    Expert Opin Biol Ther; 2020 Dec; 20(12):1427-1434. PubMed ID: 32779950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologics in severe asthma: Outcomes in clinical trials-Similarities and differences.
    Bakakos A; Rovina N; Loukides S; Bakakos P
    Expert Opin Biol Ther; 2022 Jul; 22(7):855-870. PubMed ID: 35712995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updates on the Management of Severe Asthma.
    Siddiqui A; Kopas L
    Methodist Debakey Cardiovasc J; 2017; 13(2):82-83. PubMed ID: 28740590
    [No Abstract]   [Full Text] [Related]  

  • 32. Biological treatments for severe asthma: where do we stand?
    Busse WW
    Curr Opin Allergy Clin Immunol; 2018 Dec; 18(6):509-518. PubMed ID: 30299397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?
    Upham JW; Jurak LM
    Clin Exp Allergy; 2020 Sep; 50(9):994-1006. PubMed ID: 32569412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologics for severe asthma and beyond.
    Mümmler C; Milger K
    Pharmacol Ther; 2023 Dec; 252():108551. PubMed ID: 37907197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologics for severe asthma-Which, when and why?
    Shah PA; Brightling C
    Respirology; 2023 Aug; 28(8):709-721. PubMed ID: 37222237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the current role of biologics in the management of patients with severe refractory asthma?
    Draikiwicz S; Oppenheimer J
    Ann Allergy Asthma Immunol; 2016 May; 116(5):383-7. PubMed ID: 27153737
    [No Abstract]   [Full Text] [Related]  

  • 37. Biological treatments for severe asthma: A major advance in asthma care.
    Busse WW
    Allergol Int; 2019 Apr; 68(2):158-166. PubMed ID: 30792118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.
    Heffler E; Paoletti G; Giorgis V; Puggioni F; Racca F; Del Giacco S; Bagnasco D; Caruso C; Brussino L; Rolla G; Canonica GW
    Expert Rev Clin Immunol; 2019 Sep; 15(9):951-958. PubMed ID: 31389304
    [No Abstract]   [Full Text] [Related]  

  • 39. Severe asthma and biologics: Data are good, listening to patients is better.
    Bukstein DA; Guerra DG
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):285-286. PubMed ID: 34479728
    [No Abstract]   [Full Text] [Related]  

  • 40. Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics.
    Bourdin A; Brusselle G; Couillard S; Fajt ML; Heaney LG; Israel E; McDowell PJ; Menzies-Gow A; Martin N; Mitchell PD; Petousi N; Quirce S; Schleich F; Pavord ID
    J Allergy Clin Immunol Pract; 2024 Apr; 12(4):809-823. PubMed ID: 38280454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.